Posted by Michael Wonder on 15 Jul 2020
Deciphera announces Australian Therapeutic Goods Administration’s approval of Qinlock (ripretinib) for the treatment of fourth-line gastro-intestinal stromal tumour
14 July 2020 - Qinlock is the first approved tyrosine kinase inhibitor designed specifically for GIST regardless of patients’ mutational status.
Deciphera Pharmaceuticals today announced that the Australian Therapeutic Goods Administration (TGA) has approved Qinlock (ripretinib), a switch-control tyrosine kinase inhibitor, for the treatment of adult patients with advanced gastro-intestinal stromal tumour (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
The Qinlock marketing authorisation application was approved by the TGA under Project Orbis, an initiative of the U.S. FDA Oncology Center of Excellence designed to provide a framework for concurrent submission and review of oncology products among international partners.
